F1000Research
(Mar 2020)
Antenatal corticosteroid administration for foetal lung maturation [version 1; peer review: 2 approved]
Katie Wynne,
Christopher Rowe,
Matthew Delbridge,
Brendan Watkins,
Karina Brown,
Jordan Addley,
Andrew Woods,
Henry Murray
Affiliations
Katie Wynne
Department of Diabetes & Endocrinology, John Hunter Hospital, New Lambton Heights, NSW, 2305, Australia
Christopher Rowe
Department of Diabetes & Endocrinology, John Hunter Hospital, New Lambton Heights, NSW, 2305, Australia
Matthew Delbridge
School of Medicine and Public Health, University of New England, Armidale, NSW, 2351, Australia
Brendan Watkins
School of Medicine and Public Health, University of New England, Armidale, NSW, 2351, Australia
Karina Brown
School of Medicine and Public Health, University of New England, Armidale, NSW, 2351, Australia
Jordan Addley
School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, 2308, Australia
Andrew Woods
School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, 2308, Australia
Henry Murray
School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, 2308, Australia
DOI
https://doi.org/10.12688/f1000research.20550.1
Journal volume & issue
Vol. 9
Abstract
Read online
Antenatal corticosteroids are an essential component in the management of women at risk for preterm labour. They promote lung maturation and reduce the risk of other preterm neonatal complications. This narrative review discusses the contentious issues and controversies around the optimal use of antenatal corticosteroids and their consequences for both the mother and the neonate. The most recent evidence base is presented.
WeChat QR code
Close
